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P E R S P E C T I V E
Short- and long- term evolution in our arms race with cancer: 
Why the war on cancer is winnable
Abstract
Human	society	is	engaged	in	an	arms	race	against	cancer,	which	pits	
one	evolutionary	process—human	cultural	evolution	as	we	develop	
novel	 cancer	 therapies—against	another	evolutionary	process—the	
ability	of	oncogenic	selection	operating	among	cancer	cells	to	select	
for	lineages	that	are	resistant	to	our	therapies.	Cancer	cells	have	a	
powerful	ability	to	evolve	resistance	over	the	short	term,	leading	to	
patient	relapse	following	an	initial	period	of	apparent	treatment	ef-
ficacy.	However,	we	are	the	beneficiaries	of	a	fundamental	asymme-
try	in	our	arms	race	against	cancer:	Whereas	our	cultural	evolution	
is	a	long-	term	and	continuous	process,	resistance	evolution	in	cancer	
cells	operates	only	over	 the	 short	 term	and	 is	discontinuous	—	all	
resistance	adaptations	are	lost	each	time	a	cancer	patient	dies.	Thus,	
our	 cultural	 adaptations	 are	 permanent,	whereas	 cancer’s	 genetic	
adaptations	are	ephemeral.	Consequently,	over	the	long	term,	there	
is	good	reason	to	expect	that	we	will	emerge	as	the	winners	in	our	
war	against	cancer.
1  | INTRODUC TION
The	 last	 two	 decades	 have	 seen	 a	 remarkable	 acceleration	 in	 the	
introduction	 of	 new	 drugs	 and	 other	 innovative	 therapies	 for	 the	
treatment	 of	 cancer.	 Most	 notably,	 these	 have	 included	 targeted	
chemotherapeutic	drugs,	whose	enhanced	selectivity	of	action	can	
spare	patients	 the	devastating	 side	effects	of	broad-	spectrum	cy-
totoxic	agents,	and	novel	immunotherapies,	including	both	immune	
checkpoint	blockades	and	methods	 involving	genetic	manipulation	
of	 a	 patient’s	 own	T	 cells	 (Klebanoff,	 Rosenberg,	&	Restifo,	 2016;	
Lopez	&	Banerji,	2017;	Pardoll,	2012).	The	excitement	surrounding	
these	advances	is,	however,	universally	tempered	by	the	recognition	
that	 cancer	 cells	 have	 demonstrated	 a	 powerful	 ability	 to	 evolve	
resistance	against	virtually	all	classes	of	therapies	other	than	com-
plete	surgical	excision	(Faltas	et	al.,	2016;	Gottesman,	Lavi,	Hall,	&	
Gillet,	 2016).	 After	 the	 dramatic	 initial	 successes	 of	 targeted	 che-
motherapies	for	treatment	of	chronic	myeloid	leukemia,	failures	of	
later-	introduced	drugs	have	been	profoundly	disappointing	(Gillies,	
Verduzco,	 &	 Gatenby,	 2012;	 Horne	 et	al.,	 2012;	 Schmitt,	 Loeb,	 &	
Salk,	2016).	Just	as	had	been	observed	with	the	less	selective	cyto-
toxic	chemotherapeutic	drugs	(Chabner	&	Roberts,	2005),	resistance	
has	 been	 shown	 to	 evolve	 through	 many	 mechanisms,	 including	
mutational	changes	in	the	target,	downstream	activation	of	inhibited	
pathways,	substitution	of	alternate	pathways	for	growth	activation,	
or	overexpression	of	 efflux	pumps	 (Gillies	 et	al.,	 2012;	Gottesman	
et	al.,	2016;	Schmitt	et	al.,	2016).	Failures	of	 immunotherapies	due	
to	selection	for	resistant	cancer	lineages	are	similarly	being	reported	
(Restifo,	Smyth,	&	Snyder,	2016).	This	has	called	into	question	the	fu-
ture	course	of	our	“war	on	cancer”—the	effort	to	find	a	cure	for	can-
cer	that	was	metaphorically	declared	in	1971	with	the	signing	of	the	
U.S.	National	Cancer	Act	(Marshall,	2011)—and	whether	a	definitive	
victory	is	a	realistic	expectation.	We	are	engaged	in	an	evolutionary	
arms	race	with	cancer;	can	we	anticipate	the	eventual	outcome?
Here,	I	argue	that	to	answer	this	question,	it	is	critical	to	consider	
the	 timescales	 of	 the	 evolutionary	 processes	 involved,	 including	
the	oncogenic	 (“intrasomatic”)	 selection	 in	cancer	cells	on	 the	one	
hand,	versus	the	process	of	cultural	evolution	in	human	populations,	
through	 which	 scientific	 and	 technological	 knowledge	 is	 accumu-
lated	over	time	(Mesoudi	et	al.,	2013),	on	the	other	hand.	My	thesis	
is	that	our	ability	to	build	an	ever-	expanding	set	of	anticancer	tactics	
through	 a	 long-	term	 and	 continuous	 process	 of	 cultural	 evolution	
gives	us	a	key	advantage	over	cancer	cells,	whose	resistance	adap-
tations	are	retained	only	over	the	short	term,	being	lost	every	time	
a	human	cancer	host	dies	or	the	cancer	is	cured.	Our	cultural	adap-
tations	are	permanent;	cancer’s	genetic	adaptations	are	ephemeral.	
Thus,	we	are	the	beneficiaries	of	a	fundamental	asymmetry	 in	our	
arms	race	with	cancer,	making	the	war	on	cancer	winnable.
2  | ARMS R ACES BET WEEN HUMAN 
POPUL ATIONS AND INJURIOUS 
ORGANISMS
To	frame	this	argument,	it	is	helpful	to	begin	with	more	typical	evo-
lutionary	 arms	 races	 that	 occur	 between	 human	 populations	 and	
various	 injurious	 organisms	 whose	 populations	 we	 perennially	 at-
tempt	 to	 suppress.	 Injurious	 organisms	 include	 those	 that	 attack	
us	directly	(human	parasites	and	pathogens);	organisms	that	vector	
pathogens	to	human	hosts;	organisms	that	compete	with	our	crops	
(weeds)	or	 that	directly	attack	our	crops	or	domesticated	animals;	
and	organisms	 that	attack	or	 infest	our	homes.	To	 suppress	 these	
disease	or	pest	populations,	we	deploy	a	huge	array	of	drugs,	pes-
ticides,	 and	 other	 suppressive	 measures	 on	 a	 global	 scale	 (REX	
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Consortium	2012).	 In	 each	 case,	 this	 sets	 in	motion	 an	 evolution-
ary	 arms	 race,	 pitting	 one	 long-	term	evolutionary	 process	 (human	
cultural	evolution,	as	we	invent	new	control	tactics)	against	another	
long-	term	evolutionary	process	 (evolution	of	 resistance	by	natural	
selection	 in	 the	populations	of	 the	 injurious	organisms).	There	 is	a	
symmetry	to	these	arms	races:	On	both	sides,	there	are	continuous	
processes	in	which	key	innovations	(cultural	adaptations	or	genetic	
adaptations)	can	be	retained	permanently,	resulting	in	what	Daniel	
Dennett	(1995)	has	called	the	“accumulation	of	design.”	The	power	
of	evolution	by	natural	selection	operating	across	many	generations	
is,	as	every	evolutionary	biologist	knows,	 immense;	 thus,	 it	should	
come	as	no	surprise	that	we	face	a	stiff	challenge	 in	our	attempts	
to	outpace	its	effects.	Ever-	worsening	problems	with	drug-	resistant	
bacteria	and	viruses,	and	pesticide-	resistant	weeds,	crop	pests,	and	
insect	 vectors	 of	 disease,	 show	 that	 the	 outcomes	 of	 these	 bal-
anced	evolutionary	processes	are	uncertain	(Arts	&	Hazuda,	2012;	
Goldberg,	 Siliciano,	 &	 Jacobs,	 2012;	 Kennedy	 &	 Read,	 2017;	 REX	
Consortium,	2012).	It	is	hard	to	know	if	we	will	be	able	to	stay	one	
step	ahead,	and	predictions	in	the	realm	of	antibiotic	resistance	are	
becoming	increasingly	alarming	(CDC	2013;	Davies	&	Davies,	2010;	
Dheda	et	al.,	2014).
In	 attempting	 to	 control	 populations	 of	 injurious	 organisms,	
we	 also	 may	 confront	 the	 tragedy	 of	 the	 commons	 dynamic.	
Susceptibility	 in	a	population	of	an	 injurious	organism	to	an	effec-
tive	drug	or	pesticide	is	a	genetic	resource	that	is	shared	by	society	
and	that	can	be	depleted.	Access	to	that	resource	cannot,	however,	
be	fully	controlled	by	any	 individual.	Thus,	society	encourages	pa-
tients	and	physicians	to	use	antibiotics	conservatively	and	implores	
farmers	to	use	pesticides	sparingly,	but	in	both	cases	the	prospect	of	
short-	term	personal	gains	by	heavy	users	may	lead	to	a	more	rapid	
loss	of	susceptibility	than	society	as	a	whole	would	view	as	optimal	
(Hardin,	1968;	Porco	et	al.,	2012).
3  | ARMS R ACES BET WEEN HUMAN 
POPUL ATIONS AND C ANCEROUS CELL 
LINES
We	also	 find	 ourselves	 battling	 another	 unwanted	 replicator:	Our	
own	 somatic	 cell	 lines	 that	 have	 thrown	off	 the	 normal	 restraints	
on	their	proliferation.	Just	as	is	the	case	with	our	efforts	to	control	
disease	and	pest	organisms,	our	work	to	develop	cancer	treatments	
unfolds	as	a	continuous,	long-	term	process	of	cultural	evolution.	The	
outcome	of	this	process	is	an	ever-	expanding	arsenal	of	anticancer	
drugs	(Barlas,	2016).
In	 the	 short	 term,	 cancerous	 cell	 lines	have	an	outsized	ability	
to	 evolve	 resistance	 to	 chemotherapies	 (Greaves	 &	Maley,	 2012;	
Nowell,	 1976).	This	 is	 fueled	by	what	 is	often	 a	 very	high	 level	of	
genetic	diversity	produced	by	mutation	in	cancer	cells.	The	mutation	
rate	observed	in	healthy	somatic	cell	lineages	is	substantially	higher	
than	that	observed	in	germ	cell	lineages	(Milholland	et	al.,	2017),	and	
histologically	and	physiologically	normal	somatic	cells	can,	as	a	re-
sult,	accumulate	very	large	mutational	burdens	(Martincorena	et	al.,	
2015).	On	 top	of	 this,	 some	 cancer	 cells	 exhibit	 an	 insidious	 form	
of	positive	 feedback	 that	 leads	 to	 an	 acceleration	of	 their	 genetic	
and	epigenetic	instability:	As	cancer	cells	acquire	mutations,	genes	
involved	 in	DNA	 replication,	DNA	 repair,	 and	 the	mitotic	machin-
ery	may	become	damaged,	driving	the	underlying	mutation	rate	still	
higher	(Alexandrov	et	al.,	2013;	Hanahan	&	Weinberg,	2011;	Loeb,	
2011).	In	addition,	deregulated	DNA	replication	and	uncontrolled	cell	
division	associated	with	oncogenic	transformation	can	cause	a	host	
of	problems,	 including	 telomere	erosion	and	associated	breakage–
fusion–bridge	 cycles,	 nucleoside	 imbalances,	 and	DNA	 replication	
stress,	 all	 of	which	 generate	 additional	mutations,	 including	many	
chromosomal	mutations	(Burrell,	McGranahan,	Bartek,	&	Swanton,	
2013;	Chiba	et	al.,	2017;	Maciejowski	&	de	Lange,	2017;	Mathews,	
2015;	Ren	et	al.,	2017).	An	escalating	mutation	rate	speeds	the	ac-
crual	of	still	more	mutations	in	genes	whose	function	is	to	safeguard	
the	integrity	of	the	genetic	material.	The	result	can	be	an	explosive	
evolutionary	 potential	 over	 the	 short	 term,	 such	 that	 cancer	 cells	
become	 so	 heterogeneous	 and	malleable	 that	mutants	 conferring	
resistance	 to	 virtually	 any	 therapy	 often	 exist	 before	 the	 therapy	
is	initiated	(Faltas	et	al.,	2016;	Greaves	&	Maley,	2012;	Loeb,	2011;	
Schmitt	et	al.,	2016).	Rapid	evolution	of	 resistance	 is	 thus	a	major	
obstacle	to	establishing	effective	and	durable	cancer	therapies	and	
is	the	primary	cause	of	disease	relapses	for	cancer	patients	(Aktipis,	
Kwan,	Johnson,	Neuberg,	&	Maley,	2011;	Greaves	&	Maley,	2012;	
Nowell,	1976;	Thomas	et	al.,	2013).
This	 frighteningly	 potent	 short-	term	 evolutionary	 potential	 of	
cancer	cells	is	not,	however,	matched	by	a	similarly	potent	long-	term	
evolutionary	potential.	In	fact,	cancer	cells	have	no	long-	term	evo-
lutionary	potential	at	all.	Rather,	a	defining	feature	of	oncogenic	or	
intrasomatic	selection	is	that	it	is	constrained	to	act	as	a	short-	term,	
discontinuous,	or	episodic	process,	with	each	episode	confined	 to	
events	occurring	within	a	single	host,	and	ending	abruptly	when	that	
host	dies	(from	whatever	cause)	or	the	cancer	is	cured,	eradicating	
all	cancer	cells	 (Aktipis	&	Nesse,	2013;	Arnal	et	al.,	2015;	Crespi	&	
Summers,	 2005;	 Ewald	 &	 Swain	 Ewald,	 2012;	 Haig,	 2015	 Merlo,	
Pepper,	 Reid,	 &	Maley,	 2006;	 Ujvari,	 Papenfuss,	 &	 Belov,	 2016b).	
Resistance	adaptations,	like	any	other	adaptations	that	might	evolve	
in	cancers,	thus	cannot	persist	beyond	the	death	of	each	host—there	
is	simply	no	way	for	cancer	cell	lines	(or,	at	least,	noninfectious	can-
cer	cell	 lines—see	below)	to	pass	adaptations	to	a	new	host.	Thus,	
cancer	evolution	must	start	from	scratch	with	each	new	host.	Every	
cancer	begins	 its	 evolutionary	 arms	 race	 against	our	 control	mea-
sures	as	a	naïve	combatant.
Note	that	this	line	of	reasoning	also	holds	for	cancer	driver	gene	
mutations	that	are	hereditary.	Although	a	copy	of	a	hereditary	can-
cer	driver	gene	that	is	present	in	a	tumor	cell	might	mutate,	confer-
ring	resistance	to	a	chemotherapeutic	drug,	this	mutated	version	of	
the	gene	has	no	opportunity	to	be	passed	to	offspring	of	the	cancer	
patient,	because	it	is	found	only	in	the	patient’s	tumor	cells,	which	
are	somatic	cell	lineages,	and	not	in	the	patient’s	germ	cells.
Despite	 the	 decidedly	 mixed	 record	 of	 success	 for	 newly	 in-
troduced	 cancer	 drugs,	 we	 are	 now	 beginning	 to	 see	 how	 this	
asymmetry	 in	our	 arms	 race	 against	 cancer—a	 continuous	process	
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of	cultural	evolution	pitted	against	a	discontinuous	process	of	on-
cogenic	 selection—can	give	us	 a	 decisive	 advantage	over	 the	 long	
haul.	Governmental	and,	 increasingly,	private-	sector	 investment	 in	
discovering	new	cancer	 treatments	 is	 yielding	a	 rapidly	expanding	
set	of	chemotherapeutic	agents,	immunotherapies,	and	other	ther-
apies	that	are	contributing	to	our	ability	to	suppress	cancers	(Barlas,	
2016).	Newly	introduced	drugs	can	be	useful	in	at	least	three	ways.	
First,	even	if	a	new	drug	is	no	more	effective	than	previously	devel-
oped	drugs,	 it	can	be	used	 in	a	sequence	following	other	drugs	to	
extend	the	life	of	the	patient,	providing	one	more	cycle	of	temporary	
efficacy	(Soverini	et	al.,	2014).	A	series	of	temporary	disease	remis-
sions	can	add	up	to	a	substantial	extension	of	life	for	many	patients.	
Second,	a	new	drug	may	offer	improvements	in	either	efficacy	or	in	
selectivity,	offering	a	 lessening	of	 side	effects.	Third,	and	perhaps	
most	significantly,	by	expanding	 the	set	of	effective	options	avail-
able	to	clinical	oncologists,	new	drugs	create	possibilities	for	com-
binatorial	therapies.
Combinatorial	therapies	have	emerged	as	the	main	generators	of	
cancer	cures.	They	offer	two	distinct	kinds	of	advantages:	First,	drug	
combinations	may	kill	a	greater	proportion	of	tumor	cells	than	either	
drug	used	singly	(Lopez	&	Banerji,	2017).	For	instance,	enhanced	ef-
ficacy	may	be	observed	when	an	antitumor	vaccine	is	combined	with	
an	 immune	 checkpoint	 blockade	 drug:	 Antitumor	 vaccines	 induce	
immunogenic	cell	death,	generating	a	de	novo	immune	response	that	
is	 then	coupled	with	an	 immune	checkpoint	blockade	drug,	which	
ensures	that	the	 immune	response	 is	not	subsequently	downregu-
lated	by	tumor	cells	(Vilgelm,	Johnson,	&	Richmond,	2016).	Second,	
combinatorial	 therapies	 are	 increasingly	 recognized	 as	 our	 most	
powerful	means	of	preventing	cancer	cells	from	evolving	resistance	
(Hanahan,	2014;	Kaiser,	2011;	Loeb,	2011;	Lopez	&	Banerji,	2017).	In	
fact,	combinatorial	strategies	appear	to	retard	resistance	evolution	
in	diverse	settings	where	resistance	evolution	is	an	especially	acute	
concern	 (Goldberg	 et	al.,	 2012;	Zur	Wiesch,	Kouyos,	 Engelstädter,	
Regoes,	&	Bonhoeffer,	2011):	Drug	cocktails	have	provided	a	means	
of	 coping	 with	 drug-	resistant	 bacterial	 and	 viral	 pathogens	 (e.g.,	
Mycobacterium tuberculosis,	 Gandhi	 et	al.,	 2010;	H. pylori,	Hu,	 Zhu,	
&	Lu,	2017;	HIV,	Arts	&	Hazuda,	2012),	and	toxin	combinations	can	
effectively	 slow	 resistance	 evolution	 in	 insect	 herbivores	 feeding	
on	 transgenic	 crop	 plants	 (Carrière,	 Fabrick,	 &	 Tabashnik,	 2016).	
Resistance	 evolution	 against	 vaccines	 appears	 to	 be	 rare	 largely	
because	vaccines	induce	immune	responses	against	multiple	thera-
peutic	targets	on	the	pathogen	simultaneously,	thus	generating	the	
multiple	redundant	pathways	to	pathogen	killing	that	are	at	the	heart	
of	the	combination	strategy	(Kennedy	&	Read,	2017).
The	logic	underlying	the	efficacy	of	combinations	is	simple	(REX	
Consortium	2012):	Returning	to	the	case	of	cancer	cells,	if	clones	re-
sistant	to	any	single	drug	are	present	at	low	frequency	(say,	1	×	10−5),	
then	given	 the	huge	number	of	cells	present	 in	even	small	 tumors	
(frequently	>108;	Loeb,	2011),	we	expect	>103	cells	to	be	resistant,	
and	use	of	a	single	drug	is	bound	to	fail,	as	has	sadly	been	abundantly	
confirmed	 in	 practice.	 But	 combining	 two	 drugs	 raises	 the	 bar:	 If	
each	drug	can	kill	susceptible	tumor	cells	using	an	independent	mode	
of	 action,	 then	 only	 clones	 harboring	 two	mutations	 can	 survive,	
and	 such	 clones	 are	 expected	 to	 be	 rare:	 (1	×	10−5)	×	(1	×	10−5)	=	 
(1	×	10−10).	This	is	true	regardless	of	how	diverse	the	mutations	con-
ferring	resistance	to	a	particular	drug	might	be	(and	they	are	often	
very	diverse:	e.g.,	Khorashad	et	al.,	2013).	By	extending	this	to	three	
or	four	drugs,	we	make	it	increasingly	unlikely	that	a	full	set	of	requi-
site	resistance-	conferring	mutations	will	be	found	in	any	single	can-
cer	cell.	This	is	why	many	of	the	dramatic	successes	achieved	in	the	
early	decades	of	the	war	on	cancer—those	yielding	high	cure	rates—
involved	 deploying	 multiple	 cytotoxic	 chemotherapies	 together	
(e.g.,	 methotrexate	+	vincristine	+	6-	mercaptopurine	+	prednisone,	
“POMP,”	 for	 childhood	 acute	 lymphoblastic	 leukemia;	 nitrogen	
mustard	+	vincristine	+	procarbazine	+	prednisone,	 “MOPP”,	 for	
Hodgkin’s	 lymphoma	 [Chabner	 &	 Roberts,	 2005],	 platinum	+	vin-
blastine	+	bleomycin,	 “PVB,”	 for	 testicular	 cancer	 [Einhorn,	 1981]).	
Combinatorial	 therapies	 can	 still	 fail	when	mutations	 emerge	 that	
confer	 broad-	spectrum	 resistance	 (e.g.,	multi-	drug	 resistance	 gen-
erated	by	overexpression	of	drug	efflux	pumps;	Yang	&	Fu,	2015;	
Gottesman	et	al.,	2016;	see	also	Baym,	Stone,	&	Kishony,	2016),	and	
combinatorial	therapies	also	must	be	balanced	against	the	severity	
of	 side	 effects	 (Lopez	&	Banerji,	 2017)	 and	potentially	 prohibitive	
costs.	But	combinatorial	therapies	built	with	increasingly	selective,	
targeted	 chemotherapies	 and	 with	 immunotherapies	 (e.g.,	 Hodi	
et	al.,	2016;	Vilgelm	et	al.,	2016;	Wolchok	et	al.,	2013)	hold	tremen-
dous	promise	for	expanding	the	set	of	curable	cancers.	Expanding	
opportunities	for	combinatorial	therapies	are	some	of	the	sweetest	
first	 fruits	 of	 the	 long-	term	 cultural	 evolution	 process	 playing	 out	
within	the	oncological	research	community.
Our	steady	progress	in	the	development	of	more	effective	can-
cer	therapies	is	also	unfolding	without	the	ethical	dilemma	that	we	
would	encounter	if	cancer	therapy	were	to	conform	to	the	tragedy	of	
the	commons.	Because	resistance	adaptations	in	cancer	patients	are	
confined	to	each	treated	individual,	no	patient	or	oncologist	has	ever	
had	to	ask	whether	a	too-	aggressive	treatment	might	produce	a	re-
sistant	cancer	clone	that	could	jeopardize	a	future	patient.	Difficult	
societal	choices	may	still	need	to	be	made	because	of	cost	consid-
erations,	but	these	choices	can	be	made	knowing	that	the	efficacy	
of	a	drug	regimen	in	a	future	patient	will	not	be	influenced	by	how	a	
current	patient	is	treated.
4  | INFEC TIOUS AND PATHOGEN- 
A SSOCIATED C ANCERS
The	line	of	reasoning	I	have	been	developing	applies	only	to	cancers	
that	cannot	move	between	hosts	 (noninfectious	cancers)	and	can-
cers	that	are	not	associated	with	pathogens.	But	approximately	15%	
of	all	human	cancers	worldwide	are	known	to	be	caused	by	patho-
gens	(Lunn,	Jahnke,	&	Rabkin,	2017;	Plummer	et	al.,	2016),	and	some	
observers	suggest	the	true	figure	may	prove	to	be	higher	(Ewald	&	
Swain	 Ewald,	 2012).	 Pathogens	 are	 more	 different	 biochemically	
from	healthy	human	cells	than	are	human	tumor	cells,	offering	greater	
opportunities	 for	 selective	 toxicity	 (Ewald	 &	 Swain	 Ewald,	 2014,	
2015),	 as	well	 as	more	abundant	preventive	approaches	 to	cancer	
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(e.g.,	 vaccination).	 Capitalizing	 on	 these	 opportunities,	 advances	
in	 the	 treatment	 some	pathogen-	associated	cancers	are	beginning	
to	 reduce	 cancer	 incidence	 and	 mortality	 (Casper	 &	 Fitzmaurice,	
2016;	Ewald	&	Swain	Ewald,	2014;	Global	Burden	of	Disease	Cancer	
Collaboration	2017;	Plummer	et	al.,	2016).	But,	might	the	evolution-
ary	 continuity	 within	 pathogen	 populations	 cause	 our	 arms	 race	
with	 these	cancers	 to	unfold	 in	a	qualitatively	different,	and	more	
adverse,	 way?	 Although	 this	 discussion	 is	 admittedly	 somewhat	
speculative,	 it	 is	useful	to	distinguish	between	different	categories	
of	possible	cancer	infection	potential	(Table	1).
First,	 as	already	discussed,	are	cancers	 that	are	not	associated	
with	pathogens.	These	cancers	have	a	very	strong	capacity	for	short-	
term	evolution,	but	no	ability	to	evolve	resistance	in	the	long	term,	
across	hosts.
Second	are	pathogens,	most	of	which	are	extracellular,	that	cause	
cancer	 largely	 by	 eliciting	 chronic	 inflammation	 or	 immune	 sup-
pression	 in	 their	 host.	 Inflammation	 increases	 cancer	 risk	 through	
several	pathways,	including	by	enhancing	production	of	reactive	ox-
ygen	and	nitrogen	species	that	damage	DNA	and	producing	various	
proliferative	signals	(Alibek,	Kakpenova,	&	Baiken,	2013;	Brennan	&	
Garrett,	2016;	Ewald	&	Swain	Ewald,	2014;	Graham,	2015).	Immune	
suppression	disrupts	immune	surveillance	of	cancer,	resulting	in	broad	
increases	 in	 cancer	 risk	 (e.g.,	Schistosoma	 spp.,	HIV;	Ewald	&	Swain	
Ewald,	 2012,	 2013,	 2014,	 2015).	 The	 fitness	of	 these	pathogens	 is	
not	directly	enhanced	by	neoplasia	 in	 their	host.	 Instead,	 they	may	
benefit	 from	 the	 inflammation	 of	 host	 tissues,	which	may	 increase	
the	 availability	 of	 nutrients	 (e.g.,	Helicobacter pylori;	Graham,	 2015;	
D.	 Y.	 Graham,	 personal communication)	 or	 from	 the	 suppression	 of	
the	host’s	 immune	system,	which	enables	 these	parasites	 to	estab-
lish	chronic	infections,	thereby	enhancing	opportunities	for	pathogen	
transmission	(e.g.,	H. pylori,	Wang,	Zhu,	&	Shao,	2013;	Xie	et	al.,	2017).	
The	extent	to	which	these	pathogens	evolve	to	oppose	our	anticancer	
therapies	depends	on	the	details	of	our	intervention.	If	the	antican-
cer	interventions	involve	treatments	directed	against	the	pathogens	
themselves,	then	we	face	the	full	power	of	a	continuous	evolutionary	
process	 favoring	resistance	evolution.	For	example,	antibiotic	 treat-
ments	for	H. pylori	are	a	standard	treatment	for	gastric	cancers,	and	
not	surprisingly	resistant	H. pylori	are	a	growing	clinical	concern	(Hu	
TABLE  1 Categories	of	the	infection	potential	of	cancera,	and	possible	consequences	for	cancer	resistance	evolution	to	chemotherapies
Category of cancer Implications for cancer’s evolution of resistance to therapies Taxa involved
1.	Cancers	unrelated	
to	infection
Evolution	of	resistance	only	over	the	short	term,	within	individual	patients.	No	long-	term	
evolutionary	process	exists.
Human	somatic	cell	
lines
2.	Cancers	associated	
indirectly	with	
infection,	because: 
(a)	infections	cause	
chronic	inflamma-
tion,	which	is	
oncogenic,	or	 
	(b)	infections	
suppress	immune	
surveillance,	which	
increases	survival	of	
cells	transforming	to	
cancer
Evolution	of	resistance	only	over	the	short	term,	but	pathogen	could	evolve	resistance	to	
some	cancer	therapies	over	the	long	term.	If	cancer	reduces	pathogen	fitness	by	truncating	
host	longevity,	then	natural	selection	might	favor	reduced	oncogenicity	in	pathogens,	all	
other	things	being	equal.
Helicobacter pylori
Human	immunodefi-
ciency	virus	(HIV)	 
Plasmodium falciparum
Toxoplasma gondii
Trichomonas vaginalis
Schistosoma	spp.	 
Opisthorchis viverrini
Clonorchis sinensis
3.	Cancers	directly	
caused	by	infection	
with	intracellular	
pathogen;	clonal	
expansion	of	
infected	cells	may	
enhance	virus	fitness	
(i)	by	enhancing	the	
replication	of	the	
pathogens	or	(ii)	by	
evading	host	
immune	responses	
by	opposing	
cell-	cycle	arrest	and	
apoptosis
Cancer	evolves	only	over	the	short	term,	but	the	pathogen	evolves	over	the	long	term.	
Because	the	cancer	is	an	extended	phenotype	of	the	pathogen,	evolution	within	the	
pathogen	genome	might	oppose	our	therapeutic	interventions.	If	pathogen	fitness	is	
reduced	by	malignant,	metastatic	cancer	because	they	reduce	host	longevity,	pathogen	
evolution	might	not	oppose	some	therapies	that	impose	stability	on	cancers	rather	than	
outright	cures.
Epstein–Barr	virus	
(EBV)	 
Hepatitis	B	virus	
(HBV)	 
Hepatitis	C	virus	
(HCV)	 
Human	papillomavirus	
(HPV)	 
Human	T-	
lymphotropic	virus	
type	1	(HTLV-	1)	 
Kaposi’s	sarcoma-	
associated	herpes	
virus	(KSHV)	 
Merkel	cell	polyoma-
virus	(MCV)
4.	Infectious	
cancerous cell lines
Cancer	evolves	resistance	over	the	short	and	long	terms. Unknown	in	human	
populations
aFrom	Hu,	Yang,	Wu,	Wong,	and	Fung	(2012);	Ewald	and	Swain	Ewald	(2012,	2013,	2014,	2015);	Alibek	et	al.	(2013);	Wang	et	al.	(2013);	Graham	(2015);	
Plummer	et	al.	(2016);	Chang	et	al.	(2017);	Lunn	et	al.	(2017);	Xie	et	al.	(2017).
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et	al.,	2017).	If,	however,	we	treat	the	cancer	itself,	for	instance	with	
cytotoxic	agents	or	targeted	chemotherapies,	then	our	interests	often	
do	not	conflict	with	the	evolutionary	interests	of	the	pathogen,	and	
thus,	we	should	not	expect	pathogen	evolution	to	oppose	our	cancer	
treatments.	Pathogens	that	rely	on	creating	partial	immunosuppres-
sion	of	their	hosts	might,	however,	evolve	to	oppose	cancer	immuno-
therapies	if	enhanced	immune	activity	 is	also	expressed	against	the	
pathogen.	In	all	cases,	once	a	cancer	progresses	to	a	more	malignant,	
metastatic	 state	and	 threatens	 to	kill	 the	host,	 the	evolutionary	 in-
terests	of	the	human	host	and	the	pathogen	may	become	aligned	in	
favoring	ongoing	host	survival	(Ewald	&	Swain	Ewald,	2015),	and	the	
pathogens	are	not	expected	to	oppose	anticancer	therapies.
Third	are	intracellular,	viral	pathogens	for	which	the	initial	pro-
liferation	 of	 infected	 host	 cells	may	 enhance	 fitness	 in	 two	ways.	
First,	proliferation	of	infected	cells	may	directly	augment	the	replica-
tion	of	viral	genome	(Ewald	&	Swain	Ewald,	2012,	2013).	Second,	in	
cases	where	host	immune	responses	to	virus-	infected	cells	involves	
the	initiation	of	cell-	cycle	arrest	and	programmed	cell	death,	viruses	
may	enhance	 their	 survival	by	opposing	cell-	cycle	arrest,	with	un-
controlled	 cell	 proliferation	 as	 a	 consequence	 (Chang,	 Moore,	 &	
Weiss,	2017).	Evolution	 in	 these	viral	populations	will,	 in	both	 the	
short	and	long	terms,	oppose	both	direct	antiviral	treatments	(e.g.,	
in	response	to	screen-	and-	treat	programs	against	hepatitis	B	and	C	
virus	 infections;	 Plummer	 et	al.,	 2016)	 and	 anticancer	 treatments.	
We	have,	however,	made	great	strides	 in	preventing	at	 least	some	
of	 these	 cancers	with	 vaccines	 (human	papillomavirus,	 hepatitis	B	
virus;	Plummer	et	al.,	2016;	Lunn	et	al.,	2017),	which	have	proven	to	
be	much	more	durable	in	the	face	of	pathogen	evolution	than	have	
treatments	targeting	established	infections	(Kennedy	&	Read,	2017).	
Established	infections	of	oncogenic	viruses	should	evolve	to	oppose	
our	 cancer	 therapies,	 but	 it	 is	 unclear	 how	 readily	 viruses	 could	
manipulate	the	cancer	phenotype	of	their	host’s	cells	to	evade	our	
treatments;	empirical	work	on	this	question	is	needed.	Furthermore,	
the	finding	that	many	tumor	cells	host	only	latent	or	“pseudolatent”	
viruses	that	are	not	actively	replicating	(Chang	et	al.,	2017)	suggests	
that	viral	evolution	may	not	strongly	oppose	anticancer	treatments.	
Once	the	cancer	progresses	to	threaten	host	survival,	the	evolution-
ary	interests	of	the	cancer	cells	and	the	oncogenic	virus	are	no	lon-
ger	well	aligned	(Chang	et	al.,	2017;	Ewald	&	Swain	Ewald,	2015)	and	
the	reproductive	value	of	viruses	remaining	in	the	host	will	be	low;	
thus,	oncogenic	viruses	may	not	strongly	oppose	treatments	of	met-
astatic	 cancer,	especially	 if	 they	arrest	 cancer	development	 rather	
than	creating	an	outright	cure.
Finally,	we	have	the	case	of	contagious	cancers,	in	which	can-
cer	cells	themselves	are	capable	of	moving	between	different	host	
individuals.	Infectious	cancers	have	been	found	in	dogs,	Tasmanian	
devils,	and	a	diverse	group	of	marine	gastropods	(Metzger	&	Goff,	
2016;	 Metzger	 et	al.,	 2016;	 Ujvari,	 Gatenby,	 &	 Thomas,	 2016;	
Ujvari,	Papenfuss	et	al.,	2016),	but,	happily,	not	in	human	popula-
tions.	An	infectious	human	cancer	would	be	a	nightmare	scenario	
for	resistance	evolution,	as	the	powerful	short-	term	evolutionary	
potential	of	cancer	cells	would	be	extended	to	a	longer-	term,	con-
tinuous	process.	Although	the	genomic	instability	of	most	human	
cancers	might	not	be	sustainable	over	longer	periods	of	time,	due	
to	catastrophic	mutation	accumulation	(Andor,	Maley,	&	Ji,	2017;	
Arnal	et	al.,	2015),	the	strong	mortality	imposed	on	host	popula-
tions	by	some	newly	emerged	contagious	cancers	 (Epstein	et	al.,	
2016;	Metzger	 &	Goff,	 2016)	 shows	 how	 fortunate	we	 are	 that	
we	 lack	any	 such	cell	 lines.	Our	highly	polymorphic	major	histo-
compatibility	 complex	 (MHC)	 loci	 are	 likely	 our	 primary	defense	
against	 the	 future	 emergence	 of	 such	 cancers	 (Ujvari,	 Gatenby	
et	al.,	2016;	Ujvari,	Papenfuss	et	al.,	2016).
Thus,	although	the	timescale	of	the	arms	race	between	human	
populations	 and	 pathogen-	associated	 cancers	 may	 be	 more	 sym-
metrical	 than	 the	 arms	 race	 between	 humans	 and	 nonpathogen-	
associated	cancers,	the	picture	that	emerges	is	not	entirely	bleak.	If	
we	can	devise	cancer	therapies	that	reduce	the	extent	to	which	our	
interests	are	orthogonal	to	the	 interests	of	the	pathogens,	we	will	
avoid	the	full	brunt	of	long-	term,	evolved	opposition	to	our	interven-
tions	in	pathogen	populations.
5  | CONCLUSION
The	war	on	cancer	has	struggled	during	its	first	four	decades	to	make	
major	 inroads	 on	 cancer	 mortality	 (Barlas,	 2016;	 Global	 Burden	 of	
Disease	Cancer	Collaboration	2017;	Marshall,	2011;	Mukherjee,	2010).	
This	is,	to	a	large	degree,	due	to	cancer’s	prodigious	short-	term	ability	to	
evolve	resistance	to	our	therapeutic	interventions.	But,	with	our	ability	
to	mount	a	sustained,	continuous	process	of	cultural	evolution,	in	which	
every	increase	in	our	knowledge	and	every	therapeutic	tool	devised	is	
permanently	retained,	it	was	reasonable	to	expect	that	the	tide	would	
eventually	turn.	The	Achilles’	heel	of	cancer	is	that	it	cannot	retain	its	
resistance-	conferring	adaptations	across	different	hosts.	Whether	with	
small,	incremental	steps,	or	large,	dramatic	leaps	forward,	the	cumula-
tive	progress	in	our	ability	to	treat	cancer	will,	in	the	end,	reveal	the	war	
on	cancer	to	be	winnable.
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